Application of SHP099 and its derivatives in the preparation of drugs for treating or relieving postherpetic neuralgia

SHP099 and its derivatives, administered via intrathecal injection, reduce viral load, alleviate neuroinflammation, and promote the expression of neuroprotective factors, thus addressing the problem of poor efficacy of existing drugs in relieving PHN and achieving significant relief of hyperalgesia and neuroprotective effects.

CN122229847BActive Publication Date: 2026-11-10THE NAVAL MEDICAL UNIV OF PLA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202610579210.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-04-29
Publication Date
2026-11-10
Estimated Expiration
2046-04-29

AI Technical Summary

Technical Problem

Existing medications for treating postherpetic neuralgia (PHN) offer only limited symptom relief and are accompanied by adverse reactions, resulting in a lack of effective treatment options.

Method used

Using SHP099 and its derivatives, the drug acts directly on the central nervous system by reducing viral load, alleviating neuroinflammation, promoting the expression of neuroprotective factors, reducing axonal demyelination, and relieving mechanical hyperalgesia.

Benefits of technology

It significantly alleviates mechanical hyperalgesia in PHN mice, reduces viral load, inhibits neuroinflammation, promotes the expression of neuroprotective factors, and reduces neuropathological damage, providing a novel treatment strategy for PHN.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122229847B_ABST
    Figure CN122229847B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedicine, specifically providing the application of SHP099 and its derivatives in the preparation of drugs for treating or alleviating postherpetic neuralgia (PHN). This invention provides the application of SHP099 or its pharmaceutically acceptable derivatives as active ingredients in reducing HSV-1 viral load and pro-inflammatory factor expression in the dorsal horn of the spinal cord, while simultaneously upregulating neurotrophic factor levels. This invention discovers that SHP099 or its pharmaceutically acceptable derivatives can significantly alleviate mechanical hyperalgesia in PHN model animals, and that intrathecal administration enhances efficacy and reduces systemic side effects. This invention expands the clinical application of SHP099 and provides a new strategy for PHN treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedicine, and more particularly to the use of SHP099 and its derivatives in the preparation of medicaments for treating or relieving postherpetic neuralgia. Background Technology

[0002] Postherpetic neuralgia (PHN) is one of the most common complications caused by the reactivation of the varicella-zoster virus (VZV). It manifests as neuropathic pain that persists for months or even years after the rash has healed, severely impacting patients' quality of life. Epidemiological surveys show that approximately 9%–14% of shingles patients develop PHN, and this proportion can exceed 50% in unvaccinated individuals over 85 years of age. Currently, clinically used drugs for PHN mainly include calcium channel modulators (such as gabapentin and pregabalin), tricyclic antidepressants (such as amitriptyline), and topical lidocaine patches. However, these treatments only provide limited symptom relief and are often accompanied by adverse reactions such as dizziness and drowsiness. Therefore, finding new therapeutic drugs and developing more effective PHN treatment strategies is of significant clinical importance and urgency.

[0003] The pathogenesis of chronic neuropathic pain (PHN) is complex, involving multiple factors such as viral reactivation, neuroinflammation, neuronal damage, and central sensitization. Herpes simplex virus (VZV), belonging to the alpha-herpesvirus subfamily, is neurotropic and can establish latent infection in sensory ganglia. When the body's immunity declines, VZV reactivates and spreads along nerve axons, causing neuroinflammation and tissue damage, ultimately leading to chronic neuropathic pain. Due to VZV's strict human tropism, it is difficult to study directly in rodent models. Herpes simplex virus type 1 (HSV-1), which also belongs to the alpha-herpesvirus subfamily, is widely used as an animal model for studying the pathogenesis of PHN due to its similar biological characteristics.

[0004] SHP099 is a selective, orally active allosteric inhibitor of the tyrosine phosphatase SHP2. SHP2 is a protein tyrosine phosphatase encoded by the PTPN11 gene, involved in the regulation of multiple cellular signaling pathways, including RAS-ERK, PI3K-AKT, and JAK-STAT. In recent years, SHP099 has attracted considerable attention as an anti-tumor drug and has entered clinical trials in various solid tumors and hematological malignancies, demonstrating favorable pharmacokinetic properties and safety. However, whether SHP099 can be used to treat PHN remains unreported. Summary of the Invention

[0005] The first aspect of the invention provides the use of SHP099 and / or SHP099 derivatives in the preparation of medicaments for treating or relieving postherpetic neuralgia.

[0006] Specifically, the structural formula of the SHP099 is shown in formula (Ⅰ).

[0007]

[0008] Equation (Ⅰ) Specifically, the SHP099 derivatives include pharmaceutically acceptable salts, solvates, isomers, prodrugs, metabolites, and analogs of SHP099.

[0009] Specifically, the drug treats or relieves postherpetic neuralgia through at least one of the following mechanisms: (a) Reduce viral load; (b) Reduce neuroinflammatory response; (c) Promotes the expression of neuroprotective factors; (d) Reduce axonal demyelination; (e) Reduce mitochondrial edema; (f) Relieve mechanical hyperalgesia.

[0010] More specifically, the reduction of neuroinflammatory response includes inhibiting the expression of TNF-α and IL-1β.

[0011] More specifically, the promotion of neuroprotective factor expression includes upregulating the expression of BDNF, NG, and MAG.

[0012] A second aspect of the invention provides a pharmaceutical composition for treating or relieving postherpetic neuralgia, the pharmaceutical composition comprising a therapeutically effective amount of SHP099 and / or its pharmaceutically acceptable derivatives.

[0013] Specifically, the pharmaceutical composition further includes pharmaceutically acceptable excipients, including but not limited to at least one of binders, fillers, disintegrants, lubricants, preservatives, antioxidants, flavoring agents, fragrances, solubilizers, emulsifiers, solubilizers, or osmotic pressure regulators.

[0014] More specifically, the excipients include, but are not limited to, at least one of: lactose, mannitol, methylcellulose, benzoic acid, sorbic acid, food coloring and / or talc.

[0015] Specifically, the dosage forms of the pharmaceutical composition include, but are not limited to, liquid solutions, lyophilized powders, tablets, capsules, granules, sprays, implants, creams, ointments, patches, sustained-release formulations, or suppositories.

[0016] Specifically, the administration methods of the pharmaceutical composition include, but are not limited to, oral, injection, implantation, external application, spray, inhalation, or combinations thereof.

[0017] More specifically, the injection includes, but is not limited to, intrathecal injection, intravenous injection, intramuscular injection, or subcutaneous injection.

[0018] Preferably, the injection is an intrathecal injection.

[0019] A third aspect of the invention provides a method for treating or relieving postherpetic neuralgia, the method comprising administering to a subject a therapeutically effective amount of any of the above-described pharmaceutical compositions.

[0020] The term "subject" includes living organisms (e.g., mammals) that can elicit an immune response. Examples of subjects include humans, primates, cattle, horses, goats, sheep, dogs, cats, mice, rats, rabbits, guinea pigs, pigs, and their transgenic species.

[0021] The terms “treat” or “treatment” or “ameliorate” refer to the medical management of a subject’s disease, condition, or undesirable condition. Treatment or preventative benefits include improved clinical outcomes; reduction or alleviation of symptoms associated with the disease, condition, or undesirable condition; reduced symptom occurrence; improved quality of life; longer disease-free status; reduction in the severity of the disease, condition, or undesirable condition; stabilization of the disease state; delay in disease progression; remission; survival; prolonged survival; or any combination thereof.

[0022] The term "therapeutic effective dose" refers to a pharmaceutically considered effective dosage, that is, an amount of active drug sufficient to significantly improve the condition without causing serious side effects. Dosage depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight, personality, and individual response of the patient or animal, the route of administration, frequency of administration, and therapeutic purpose; therefore, the dosage of this invention can vary widely.

[0023] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention is the first to apply SHP099 to the treatment of PHN, and it has been shown that it can significantly alleviate mechanical hyperalgesia in PHN mice, providing a novel candidate drug for the clinical treatment of PHN.

[0024] 2. This invention systematically verified the therapeutic effect of SHP099 from multiple levels, including behavioral (mechanical pain threshold), virology (viral load), immunology (inflammatory factors), molecular biology (neuroprotective factors), and pathology (transmission electron microscopy). It confirmed that SHP099 can reduce viral load, inhibit neuroinflammation, promote the expression of neuroprotective factors, and alleviate neuropathological damage, thus playing a synergistic role in the treatment of PHN.

[0025] 3. Promising prospects for clinical translation: SHP099, as a small molecule compound that has entered clinical trials in the field of oncology, has good pharmacokinetic properties and known safety characteristics. Its novel use in the treatment of PHN has high clinical translational value.

[0026] 4. This invention uses intrathecal injection to deliver the drug directly to the lesion site in the central nervous system, which improves the efficacy, reduces systemic adverse reactions, and provides a new drug delivery strategy for the treatment of PHN. Attached Figure Description

[0027] Figure 1 To detect the mechanohyperalgesia of the plantar skin of PHN mice in the SHP099 treatment group and solvent control group using von Frey fibers, A represents the detection results of 0.6g von Frey fibers and B represents the detection results of 2g von Frey fibers.

[0028] Figure 2 To detect the mechanical hyperalgesia of von Frey fibers in the skin lesions of PHN mice in the SHP099 treatment group and solvent control group, A represents the detection results of 0.6g von Frey fibers, and B represents the detection results of 2g von Frey fibers.

[0029] Figure 3 To assess the mechanical hyperalgesia of the abdominal skin of PHN mice in the SHP099 treatment group and the solvent control group using von Frey fibers, A represents the results of testing with 0.6g of von Frey fibers, and B represents the results of testing with 2g of von Frey fibers.

[0030] Figure 4 The expression level of HSV-1 TK DNA in the dorsal horn of the spinal cord of PHN mice in the SHP099 treatment group and the solvent control group was detected by Q-PCR.

[0031] Figure 5 The transcriptional levels of inflammatory factors TNF-α and IL-1β in the dorsal horn of the spinal cord of PHN mice in the SHP099 treatment group and the solvent control group were detected by Q-PCR.

[0032] Figure 6The protein levels of TNF-α and IL-1β in the dorsal horn of the spinal cord of PHN mice in the SHP099 treatment group and the solvent control group were detected by ELISA.

[0033] Figure 7 The transcriptional levels of neuroprotective factors BDNF, NG, and MAG in the dorsal horn of the spinal cord of PHN mice in the SHP099 treatment group and the solvent control group were detected by Q-PCR.

[0034] Figure 8 Transmission electron microscopy was used to show the demyelination of axons in the dorsal horn of the spinal cord of PHN mice in the SHP099 treatment group and the solvent control group (A, red arrow) and mitochondrial edema (B, blue arrow). Detailed Implementation

[0035] The present invention will be further described in detail below with reference to specific embodiments, but this should not be construed as limiting the present invention. Various changes and modifications can be made to the present invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the present invention as claimed.

[0036] Example 1: Effect of SHP099 on mechanical hyperalgesia in PHN mice 1. Experimental Materials SHP099 was purchased from Med Chem Express (catalog number HY-100388) with a purity ≥99.79%. Before use, a stock solution was prepared with DMSO, and then diluted with sterile physiological saline to the required concentration (final concentration 0.1 μg / 5 μL, final DMSO concentration 5%) just before use.

[0037] 2. Experimental Methods 2.1 Establishment of PHN Model Male C57BL / 6J mice (20-25g, 6-8 weeks old) were housed in an SPF-grade animal facility at a temperature of 24±1℃ and humidity of 50±5%, with a 12-hour light / 12-hour dark cycle and free access to food and water. Mice were acclimatized for one week before being used in experiments. After anesthesia, the hair on the back, sides, and hind limbs was trimmed with an electric razor, and fine hairs were removed with depilatory cream. Three days later, the right tibia was inoculated with HSV-1 7401H strain (1×10⁻⁶). 6 PFU (10 μL). The control group was inoculated with heat-inactivated HSV-1 (60℃, 1 hour). Mice were observed daily after inoculation for general condition, skin lesions, and behavioral changes. Herpes zoster-like skin lesions (erythema, vesicles, and crusting) appeared 7-10 days after HSV-1 infection, and the lesions completely healed by day 14, leaving scars. Mice that still exhibited mechanical hyperalgesia after day 14 were considered to have successfully developed a PHN model.

[0038] 2.2 Animal grouping and administration PHN model mice were randomly divided into two groups: a solvent control group (Vehicle) and a SHP099 treatment group (SHP099). Intrathecal administration began on day 14 post-infection and continued for three consecutive days. The SHP099 treatment group received SHP099 (0.1 μg / 5 μL), while the solvent control group received an equal volume of solvent (5% DMSO + 95% saline).

[0039] Intrathecal injection method: After isoflurane inhalation anesthesia, mice were placed in a prone position, and the lumbar intervertebral spaces (L4-L5) corresponding to the line connecting the bilateral iliac crests were located by palpation. A microsyringe connected to a 30G needle was inserted vertically into the skin, with the needle tip slightly tilted towards the head. The needle was slowly advanced about 3-5 mm, and stopped after a breakthrough sensation was felt. Gently aspirate to ensure no cerebrospinal fluid or blood flow was observed, and then slowly inject the drug (5 μL, injection time about 30 seconds). The needle was left in place for 10 seconds after injection, and then slowly withdrawn. After observing the mice for any abnormalities, they were returned to their cages. After injection, the mice exhibited normal activity and no abnormalities such as hind limb paralysis.

[0040] 2.3 Mechanical pain threshold determination Mechanical pain thresholds were measured at different time points post-infection (0, 3, 7, 10, 14, 17, 21, 24, and 28 days). Mice were acclimatized for 2 hours in transparent acrylic cages (10cm × 10cm × 15cm) with a metal mesh bottom. The skin on the soles of the feet, lesions, and abdomen was vertically stimulated with 0.6g and 2g von Frey fibers, respectively, for 2-3 seconds each time, repeated 6 times per site with a 60-second interval between each stimulation. Contact with hair and scar tissue was avoided during stimulation. Scoring criteria: 0 = no response; 1 = rapid lifting of the stimulated area; 2 = shaking or licking of the stimulated area. Pain-related score (%) = (total score / 12) × 100%. The experiment was conducted in a double-blind manner, with the experimenters unaware of the group assignments.

[0041] 3. Experimental Results 3.1 Mechanical hyperalgesia of the plantar skin Results of 0.6g von Frey fiber assays showed that in the SHP099 treatment group, pain-related scores gradually decreased after administration (Days 17, 21, 24, and 28), and were significantly lower than those in the solvent control group on Days 24 and 28 (P<0.01). Figure 1 A). The results of the 2g von Frey fiber test were consistent with those of the 0.6g test. Figure 1 B).

[0042] 3.2 Mechanical hyperalgesia at the site of skin lesion Results of 0.6g von Frey fiber assays showed that the SHP099 treatment group had significantly lower pain-related scores on Day 24 and 28 compared to the solvent control group (P<0.01). Figure 2A). The results of the 2g von Frey fiber test were consistent with those of the 0.6g test. Figure 2 B).

[0043] 3.3 Abdominal skin mechanical hyperalgesia Results of 0.6g von Frey fiber assays showed that the SHP099 treatment group had significantly lower pain-related scores on Day 24 and 28 compared to the solvent control group (P<0.05). Figure 3 A). The results of the 2g von Frey fiber test were consistent with those of the 0.6g test. Figure 3 B).

[0044] The above results indicate that intrathecal injection of SHP099 can effectively alleviate mechanical hyperalgesia of the skin on the soles of the feet, lesions, and abdomen of PHN mice, and the therapeutic effect can last for more than 10 days after administration.

[0045] Example 2: Effect of SHP099 on viral load in the dorsal horn of the spinal cord of PHN mice 1. Experimental Methods On the 24th day after infection (i.e. after the behavioral test was completed), the spinal cord of the L4-5 segment of the lumbar spine was quickly removed, the dorsal horn tissue was separated on ice, flash-frozen in liquid nitrogen, and stored at -80℃ for later use.

[0046] Take approximately 20 mg of spinal cord dorsal horn tissue, add 1 mL of TRIzol reagent, and homogenize thoroughly on ice using a homogenizer. Incubate at room temperature for 5 minutes, add 200 μL of chloroform, vortex vigorously for 15 seconds, and incubate at room temperature for 3 minutes. Centrifuge at 12000 g for 15 minutes at 4°C, transfer the upper aqueous phase to a new EP tube, add an equal volume of isopropanol, mix well, and incubate at room temperature for 10 minutes. Centrifuge at 12000 g for 10 minutes at 4°C, discard the supernatant, wash the precipitate twice with 75% ethanol, dry at room temperature, and dissolve in 20 μL of DEPC water. Determine RNA concentration and purity (A260 / A280 between 1.9 and 2.1) using a Nanodrop 2000. Take 1 μg of total RNA and reverse transcribe it into cDNA using a PrimeScript RT kit. Reaction system: 5×PrimeScript Buffer 4μL, PrimeScript RT Enzyme Mix I 1μL, OligodT Primer (50μM) 1μL, Random 6 mers (100μM) 1μL, total RNA 1μg, RNase-free dH2O to 20μL. Reaction conditions: 37℃ for 15 minutes, 85℃ for 5 seconds, store at 4℃. Q-PCR detection of HSV-1 TK gene expression: Reaction system: SYBR Premix Ex Taq II 10μL, forward and reverse primers (10μM) 0.8μL each, ROX Reference Dye II 0.4μL, cDNA template 2μL, dH2O 6μL, total system 20μL. Reaction conditions: 95℃ pre-denaturation for 30 seconds; 95℃ denaturation for 5 seconds, 60℃ annealing and extension for 34 seconds, 40 cycles. The assay was performed using an ABI QuantStudio 5 real-time quantitative PCR instrument. β-actin was used as an internal control, and a 2... -ΔΔCT The relative expression level is calculated using this method.

[0047] HSV-1 TK primer sequence: Positive 5'-ATACCGACGATATGCGACCT-3' (SEQ ID NO.1); Reverse 5'-TTATTGCCGTCATAGCGCGG-3' (SEQ ID NO. 2); β-actin primer sequence: Positive 5'-AGAGGGAAATCGTGCGTGAC-3' (SEQ ID NO.3); Reverse 5'-CAATAGTGATGACCTGGCCGT-3' (SEQ ID NO.4).

[0048] 2. Experimental Results Q-PCR results showed that HSV-1 TK DNA was positively expressed in the dorsal horn of the spinal cord of PHN mice in the solvent control group, indicating that the virus replicated in the dorsal horn of the spinal cord. The expression level of HSV-1 TK DNA in the dorsal horn of the spinal cord of mice in the SHP099 treatment group was significantly lower than that in the solvent control group (P<0.01). Figure 4 This indicates that SHP099 treatment can effectively inhibit HSV-1 replication in the dorsal horn of the spinal cord and reduce viral load.

[0049] Example 3: Effects of SHP099 on neuroinflammation in PHN mice 1. Experimental Methods Tissue from the dorsal horn of the spinal cord of mice was collected on day 24 post-infection. The tissue was divided into two parts: RNA was extracted from one part (about 10 mg), and the mRNA levels of inflammatory factors TNF-α and IL-1β were detected by Q-PCR; protein was extracted from the other part (about 10 mg) using RIPA lysis buffer, and the protein levels of TNF-α and IL-1β were detected by ELISA.

[0050] Q-PCR detection: RNA extraction and reverse transcription methods are the same as in Example 2.

[0051] TNF-α primer sequence: Positive 5'-GTAGCCCACGTCGTAGCAAA-3' (SEQ ID NO.5); Reverse 5'-ACAAGGTACAACCCATCGGC-3' (SEQ ID NO.6); IL-1β primer sequence: Positive 5'-AGAGCCCATCCTCTGTGACT-3' (SEQ ID NO.7); Reverse 5'-GCTCATATGGGTCCGACAGC-3' (SEQ ID NO.8).

[0052] β-actin was used as an internal reference. The reaction conditions and calculation methods were the same as in Example 2.

[0053] ELISA assay: RIPA lysis buffer (1:100 ratio) containing a protease inhibitor cocktail was added to the dorsal horn tissue of the spinal cord. The tissue was homogenized thoroughly on ice and centrifuged at 12000g for 15 minutes at 4°C. The supernatant was collected. Protein concentration was determined by BCA method, and the protein concentration of each sample was adjusted to 1 mg / mL. Follow the instructions for the Mouse TNF-α ELISA Kit (Invitrogen, BMS607-3) and the Mouse IL-1β ELISA Kit (Invitrogen, BMS6002): Add 100 μL of standard or sample to each well and incubate at 37°C for 90 minutes; wash the plate 4 times, add 100 μL of biotinylated antibody working solution, and incubate at 37°C for 60 minutes; wash the plate 4 times, add 100 μL of enzyme conjugate working solution, and incubate at 37°C in the dark for 30 minutes; wash the plate 4 times, add 100 μL of chromogenic substrate, and incubate at 37°C in the dark for 15-20 minutes; add 100 μL of stop solution and immediately measure the OD value at 450 nm using a microplate reader. Calculate the concentrations of TNF-α and IL-1β in each sample based on the standard curve.

[0054] 2. Experimental Results Q-PCR results: The mRNA levels of TNF-α and IL-1β in the dorsal horn of the spinal cord of mice in the SHP099 treatment group were significantly lower than those in the solvent control group (P<0.01). Figure 5 ).

[0055] ELISA results: The protein levels of TNF-α and IL-1β in the dorsal horn of the spinal cord of mice in the SHP099 treatment group were significantly lower than those in the solvent control group (P<0.01). Figure 6 ).

[0056] The above results indicate that SHP099 treatment can effectively inhibit the expression of inflammatory factors TNF-α and IL-1β in the dorsal horn of the spinal cord of PHN mice and reduce neuroinflammatory response.

[0057] Example 4: Effects of SHP099 on neuroprotective factors in PHN mice 1. Experimental Methods Tissue from the dorsal horn of the spinal cord of mice was collected on day 24 post-infection. RNA extraction and reverse transcription were performed using the same methods as in Example 2. The mRNA levels of neuroprotective factors BDNF, NG, and MAG were detected by Q-PCR.

[0058] BDNF primer sequences: Positive 5'-CCCGGTGTCGCCCTTAAAAA-3' (SEQ ID NO.9); Reverse 5'-CTCACCTGGTGGAACTTCTTTG-3' (SEQ ID NO.10); NG primer sequences: Forward 5'-AGCATCGTACAAACCCACCC-3' (SEQ ID NO.11); Reverse 5'-AAAACGTTCAGCTCTGGCCTA-3' (SEQ ID NO.12); MAG primer sequence: Forward 5'-GCGTTCCTCAGCTCCTCATT-3' (SEQ ID NO.13); Reverse 5'-CCCCCTCGAGAAGCTGAAAT-3' (SEQ ID NO.14).

[0059] β-actin was used as an internal reference. The reaction conditions and calculation methods were the same as in Example 2.

[0060] 2. Experimental Results Q-PCR results showed that the mRNA levels of BDNF, NG, and MAG in the dorsal horn of the spinal cord of mice treated with SHP099 were significantly higher than those in the solvent control group (P<0.01). Figure 7 The above results indicate that SHP099 treatment can promote the expression of neuroprotective factors BDNF, NG, and MAG, which is beneficial for nerve repair and protection.

[0061] Example 5: Effects of SHP099 on neuropathological damage in PHN mice 1. Experimental Methods On day 24 post-infection, mice from each group were subjected to transmission electron microscopy. After deep anesthesia, the thoracic cavity was opened, a cannula was inserted through the left ventricle into the ascending aorta, and the right atrial appendage was cut open. Approximately 20 mL of pre-cooled PBS (containing 10 U / mL heparin) was rapidly perfused to rinse the blood, followed by approximately 50 mL of pre-cooled 2.5% glutaraldehyde fixative (prepared with 0.1 M phosphate buffer, pH 7.4) for pre-fixation. After perfusion, the L4-5 segment of the spinal cord was quickly removed, and the dorsal horn tissue was separated on ice, cut into 1 mm³ pieces, and fixed overnight at 4°C in 2.5% glutaraldehyde. The next day, the mice were rinsed three times with 0.1 M phosphate buffer for 10 minutes each time, and then fixed for 1 hour at 4°C with 1% osmium tetroxide (prepared with 0.1 M phosphate buffer). Rinse three times with double-distilled water, then dehydrate using a gradient of ethanol (50%, 70%, 80%, 90%, 100%, 10 minutes each, repeated twice with 100% ethanol). Replace with acetone twice, 10 minutes each time. Gradient infiltration with epoxy resin Epon812 embedding agent (acetone: embedding agent = 1:1, 1 hour at room temperature; acetone: embedding agent = 1:3, 2 hours at room temperature; pure embedding agent, overnight at room temperature). After embedding, polymerize in an oven: 37℃ for 12 hours, 45℃ for 12 hours, and 60℃ for 24 hours. Cut 60nm ultrathin sections using an ultramicrotome and place them on a copper grid. Stain with uranium acetate for 15 minutes, then rinse three times with double-distilled water; stain with lead citrate for 15 minutes, then rinse three times with double-distilled water. After drying at room temperature, observe and photograph under a transmission electron microscope with an accelerating voltage of 80kV.

[0062] 2. Experimental Results Transmission electron microscopy revealed significant neuropathological damage in the dorsal horn of the spinal cord in the solvent control group PHN mice: loose axonal myelin sheath structure, lamellar separation, and breakage. Figure 8 A, red arrow), mitochondrial swelling, cristae breakage, vacuolation ( Figure 8 (B, blue arrow). In the SHP099 treatment group, the axonal myelin sheath structure in the dorsal horn of the spinal cord of mice was intact, the lamellar structure was dense, the mitochondria were of normal morphology, and the cristae were clearly visible. The degree of neuropathological damage was significantly less than that in the solvent control group. These results indicate that SHP099 treatment can effectively protect nerve cells and reduce axonal demyelination and mitochondrial damage caused by HSV-1 infection.

[0063] The above description represents the preferred embodiments of the present invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. The use of SHP099 or a pharmaceutically acceptable salt of SHP099 in the preparation of medicaments for the treatment or relief of postherpetic neuralgia, characterized in that, The drug is an intrathecal injection dosage form; The structural formula of SHP099 is shown in formula (Ⅰ): ; Equation (Ⅰ).

Citation Information

Patent Citations

  • Application of LAPF in preparation of antiviral drugs

    CN122124212A

  • SHP1 and SHP2 inhibitors and their methods of use

    US20220296616A1